Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,410 Mln
Revenue (TTM)
$510 Mln
Net Profit (TTM)
$0 Mln
ROE
0.4 %
ROCE
-- %
P/E Ratio
23.9
P/B Ratio
7.2
Industry P/E
--
EV/EBITDA
17.2
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$2
EPS
$0.6
Face value
--
Shares outstanding
238,159,176
CFO
$-489.62 Mln
EBITDA
$-313.04 Mln
Net Profit
$-506.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
| -37.9 | -30.4 | -41.9 | -42.8 | 53.9 | 40.8 | 6.2 |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
| 6.4 | 275.3 | 16.5 | 175.2 | -27.7 | -51.3 | 67.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
11.3 | 3,410.4 | 510.2 | 146.9 | 37.2 | 35.6 | 23.9 | 7.2 |
| 12.1 | 3,722.1 | 3,018.8 | 72.1 | 12.6 | -80 | 53.8 | 86.1 | |
| 158.8 | 8,027.0 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.0 | |
| 68.5 | 13,287.4 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 33.8 | 3,684.8 | 761.4 | 99.7 | 7.3 | 15 | 42.2 | 5.7 | |
| 13.5 | 11,772.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 19.6 | 3.0 | |
| 24.9 | 11,922.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.9 | |
| 7.6 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 201.7 | 4,084.1 | 268.1 | 124.5 | 60.0 | 13.5 | 33.5 | 4.0 | |
| 35.2 | 3,208.3 | 158.3 | -68.9 | -29.3 | -113 | -- | 71.7 |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates... through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Read more
Co-Founder, President, CEO & Director
Mr. Adam S. Grossman
Co-Founder, President, CEO & Director
Mr. Adam S. Grossman
Headquarters
Ramsey, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ADMA Biologics Inc (ADMA) is $11.33 (NASDAQ) as of 24-Mar-2026 16:27 EDT. ADMA Biologics Inc (ADMA) has given a return of 53.87% in the last 3 years.
The P/E ratio of ADMA Biologics Inc (ADMA) is 23.87 times as on 20-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
30.27
|
9.32
|
|
2024
|
21.33
|
12.08
|
|
2023
|
-36.17
|
7.55
|
|
2022
|
-11.94
|
5.18
|
|
2021
|
-3.56
|
1.81
|
The 52-week high and low of ADMA Biologics Inc (ADMA) are Rs 25.67 and Rs 10.90 as of 25-Mar-2026.
ADMA Biologics Inc (ADMA) has a market capitalisation of $ 3,410 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ADMA Biologics Inc (ADMA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-2.26
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.